Regulus Therapeutics Inc (RGLS)

$ 0.9151
-0.0249 (-2.65%)
Buy
Symbol RGLS
Price $ 0.9151
Beta 2.388
Volume Avg. 3.13M
Market Cap 0.07B
Shares () -
52 Week Range 0.42-2.32
1y Target Est -
DCF Unlevered -
DCF Levered -
ROE -109.87% Strong Sell
ROA -41.83% Strong Sell
Operating Margin -
Debt / Equity 44.49% Neutral
P/E -
P/B 1.68 Strong Buy
Annual
Quarter

Earnings

Consensus EPS

Upgrades & Downgrades

Regulus Therapeutics Announces Timing for First Quarter 2021 Financial Results Webcast and Conference Call

Regulus Therapeutics Announces Timing for First Quarter 2021 Financial Results Webcast and Conferenc...

SAN DIEGO, May 6, 2021 /PRNewswire/ --  Regulus Therapeutics Inc. (Nasdaq: RGLS), a biopharmaceutical company focused on the discovery and development of innovative medicines targeting microRNAs (the "Company" or "Regulus"), announced today that it w... ...

PRNewsWire
Regulus Therapeutics' RGLS4326 Reports Mixed Bag On Polycystic Kidney Disease-Associated Biomarker Study

Regulus Therapeutics' RGLS4326 Reports Mixed Bag On Polycystic Kidney Disease-Associated Biomarker S...

Regulus Therapeutics Inc (NASDAQ: RGLS) has announced top-line results from the first cohort of patients (n=9) with Autosomal Dominant Polycystic Kidney Disease (ADPKD) in its ongoing Phase 1b trial of RGLS4326. The study evaluates the safety, pharma... ...

Benzinga
Regulus Therapeutics Announces Completion of Dosing in the First Cohort of Phase 1b Clinical Trial of RGLS4326 for the Treatment of Patients with Autosomal Dominant Polycystic Kidney Disease (ADPKD)

Regulus Therapeutics Announces Completion of Dosing in the First Cohort of Phase 1b Clinical Trial o...

LA JOLLA, Calif., April 15, 2021 /PRNewswire/ -- Regulus Therapeutics Inc.  (Nasdaq: RGLS), a biopharmaceutical company focused on the discovery and development of innovative medicines targeting microRNAs (the "Company" or "Regulus"), today announced... ...

PRNewsWire
Regulus Therapeutics to Present at the 20th Annual Needham Virtual Healthcare Conference

Regulus Therapeutics to Present at the 20th Annual Needham Virtual Healthcare Conference

LA JOLLA, Calif., April 7, 2021 /PRNewswire/ -- Regulus Therapeutics Inc.  (Nasdaq: RGLS), a biopharmaceutical company focused on the discovery and development of innovative medicines targeting microRNAs ("Regulus"), today announced that Jay Hagan, P... ...

PRNewsWire
RGLS Stock Price Increased 56.8%: Why It Happened

RGLS Stock Price Increased 56.8%: Why It Happened

The stock price of Regulus Therapeutics Inc (NASDAQ: RGLS) has increased by 56.8% over the past week. This is why it happened. ...

Pulse2
RGLS Stock: 7 Things to Know About Red-Hot Regulus Therapeutics

RGLS Stock: 7 Things to Know About Red-Hot Regulus Therapeutics

Investors seem to believe something may be cooking with RGLS stock right now, given the outsized move we've seen today on a lack of news. The post RGLS Stock: 7 Things to Know About Red-Hot Regulus Therapeutics appeared first on InvestorPlace. ...

InvestorPlace
Regulus Therapeutics Reports Fourth Quarter and Year-End 2020 Financial Results and Recent Updates

Regulus Therapeutics Reports Fourth Quarter and Year-End 2020 Financial Results and Recent Updates

LA JOLLA, Calif., March 9, 2021 /PRNewswire/ --  Regulus Therapeutics Inc.  (Nasdaq: RGLS), a biopharmaceutical company focused on the discovery and development of innovative medicines targeting microRNAs (the "Company" or "Regulus"), today reported ... ...

PRNewsWire
Regulus Therapeutics to Present at the H.C. Wainwright Global Life Sciences Conference

Regulus Therapeutics to Present at the H.C. Wainwright Global Life Sciences Conference

LA JOLLA, Calif., March 5, 2021 /PRNewswire/ -- Regulus Therapeutics Inc. (Nasdaq: RGLS), a biopharmaceutical company focused on the discovery and development of innovative medicines targeting microRNAs ("Regulus"), today announced that Jay Hagan, Pr...

PRNewsWire
Regulus Therapeutics Announces Completion of Enrollment in First Cohort of Phase 1b Clinical Trial of RGLS4326 for the Treatment of Patients with Autosomal Dominant Polycystic Kidney Disease (ADPKD)

Regulus Therapeutics Announces Completion of Enrollment in First Cohort of Phase 1b Clinical Trial o...

LA JOLLA, Calif., Feb. 10, 2021 /PRNewswire/ -- Regulus Therapeutics Inc. (Nasdaq: RGLS), a biopharmaceutical company focused on the discovery and development of innovative medicines targeting microRNAs (the "Company" or "Regulus"), today announced i...

PRNewsWire
Regulus Announces Addition to Board of Directors

Regulus Announces Addition to Board of Directors

LA JOLLA, Calif., Jan. 27, 2021 /PRNewswire/ -- Regulus Therapeutics Inc. (Nasdaq: RGLS), a biopharmaceutical company focused on the discovery and development of innovative medicines targeting microRNAs, today announced Alice S. Huang, Ph.D. has been...

PRNewsWire

About


Mr. Joseph Hagan
Healthcare
Biotechnology
Nasdaq Global Market

Regulus Therapeutics Inc., a clinical stage biopharmaceutical company, engages in the discovery and development of drugs that target microRNAs to treat a range of diseases in the United States. Its two lead product candidates include RG-012, an anti-miR targeting miR-21 that is in Phase II clinical trial for the treatment of Alport syndrome, a life-threatening kidney disease; and RGLS4326, an anti-miR targeting miR-17, which is in Phase Ib clinical trial for the treatment of autosomal dominant polycystic kidney disease. The company is also developing a pipeline of preclinical drug products, which include RGLS5579 to inhibit miR-10b, and Hepatitis B virus program and Non-Alcoholic Steatohepatitis program. Regulus Therapeutics Inc. was founded in 2007 and is headquartered in San Diego, California.